Please login to the form below

Not currently logged in

Amgen buoyant as profits rise in Q3

Increases 2012 revenue and earnings forecasts


Amgen has boosted its 2012 revenue and earnings forecasts after posting a double-digit sales increase in the third quarter driven by arthritis drug Enbrel.

Operating income came in at $1.7bn in the quarter, a rise of 14 per cent and topping analyst estimates, while revenues climbed 10 per cent to $4.32bn, giving new chief executive Robert Bradway a great start in his first full-quarter at the helm.

"Our business has very good momentum, and we're executing on our strategy to grow the business and deliver for patients and shareholders," said Bradway on a conference call to discuss the figures.

Amgen's biggest product franchise - the white cell stimulators Neulasta (pegfilgrastim) and Neupogen (filgrastim) - held up well despite their advancing years and recording $1.34bn in third-quarter sales thanks to direct-to-consumer (DTC) and caregiver advertising.

Among Amgen's growth products, sales of Enbrel (etanercept) grew 17 per cent to $1.08bn while Xgeva (denosumab) for bone fracture prevention climbed 12 per cent to $201m.

Hyperparathyroidism drug Sensipar/Mimpara (cinacalcet) had a good quarter, up 18 per cent to $243m, while colorectal cancer drug Vectibix (panitumumab) rose 11 per cent to $88m. Nplate (romiplostim) for the treatment of chronic immune thrombocytopenic purpura climbed 18 per cent to $91m.

On the downside, Amgen's red blood cell stimulator Aranesp (darbepoetin alfa) fell 17 per cent to $497m as a result of changing practice patterns, competition in oncology and safety issues.

However, Amgen's older drug in this category – Epogen (epoetin alfa) – managed a 3 per cent gain to $491m thanks to lower-than-expected competition and resistance by dialysis providers to switch to newer drugs such as Takeda/Affymax' Omontys (peginasetide), which was approved in the US earlier this year.

"We now expect full year revenues to fall between $17.2bn and $17.3bn," said chief financial officer Jonathon Peacock, adding that earnings per share (EPS) will be in the $6.50-$6.60 range.

Amgen was previously predicting revenues of $16.9-$17.2bn in revenues and EPS of $6.20-$6.35.

Looking to 2013, Amgen expects R&D costs to rise as it ramps up phase III trials for romosozumab, a monoclonal antibody for the treatment of postmenopausal osteoporosis, and starts preparing for pivotal trials of cholesterol-lowering therapy AMG 145.

24th October 2012

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...